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Abstract
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and acquired hematopoietic stem cell disease,
with florid clinical presentations. Although this disease has been characterized in the western countries, its clinical
and laboratory features in Taiwan have not yet been reported.
Results: As a part of an international prospective, non-interventional, observational registration trial of PNH, we
have analyzed 63 patients recruited between 2009 and 2015 in Taiwan, with comparison to the 3857 patients in the
rest of the world (ROW). The median age of diagnosis of our patients is 46 (range 9–84), without sex preponderance.
While most of the clinical and laboratory presentations of our patients are similar to the ROW, ours have higher lactate
dehydrogenase levels, lower hemoglobin, and higher frequencies of symptoms including shortness of breath and
erectile dysfunction at the time of diagnosis. The incidence of thromboembolism was not statistically different
between ours and the ROW (6.7 % vs 13.5 %, P = 0.178). The patients in Taiwan were treated more frequently with
corticosteroid (53.2 % vs 32 %, P < 0.001), but less frequently with cyclosporine/anti-thymocyte globulin and heparin/
warfarin, both P < 0.001).
Conclusions: This is the first systematic review on the Taiwanese PNH patients. Our analysis would provide key
information about our PNH patients and would help understanding the basic characteristics of this rare disease in Taiwan.
Trial registration: This trial has been registered to ClinicalTrails.gov NCT01374360.
Keywords: Paroxysmal nocturnal hemoglobinuria, Taiwan
Abbreviations: CRF, Case report form; PNH, Paroxysmal nocturnal hemoglobinuria; ROW, Rest of the world;
TE, Thromboembolism
Background
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, ac-
quired chronic disease characterized by complement-
mediated hemolysis. PNH patients may suffer from life
threatening complications such as thromboembolism (TE),
pulmonary hypertension and impaired renal function; ac-
cording to a western study, up to 35 % of PNH patients die
within 5 years of diagnosis [1]. However, the clinical features
of PNH patients in Taiwan have not yet been characterized.
The International PNH Registry is a worldwide, obser-
vational, non-interventional study collecting safety and
efficacy of eculizumab, as well as other clinical data from
PNH patients, irrespective of treatment. This registry
aims to enhance the understanding of the natural history
of this rare disease, hoping to improve the diagnosis and
optimize patient management and outcomes.
The natural history of PNH has been investigated via
some analyses with different population sizes [1–5].
Schrezenmeier et al. reported the characteristics of 1610
patients in a global registry [6]. It is the first time now
that we look at the baseline characteristics of this disease
in Taiwanese PNH patients in this global PNH registry.
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The data include demographics, clinical characteristics
as well as concomitant medications. We describe the
similarities and differences between Taiwanese PNH
population and the rest of the world (ROW).
Methods
Patient population
The international PNH registry is a prospective, non-
interventional, observational study. The Registry collects
information from patients monitored in current medical
practice irrespective of past, present, or future treatment
policies. The registry was approved by the institutional
review boards (or equivalent) of participating centers,
and all patients provided written informed consent prior
to inclusion. The registry is sponsored by Alexion
Pharmaceuticals, Inc., and is overseen by an independent
executive committee of international PNH experts.
Patients of any age with a clinical diagnosis of PNH con-
firmed by Ham test or Sucrose-Lysis test in the pre-flow
cytometry era and/or detectable PNH clone of 0.1 % or
more were eligible for this registry in Taiwan. A total of 63
PNH patients were enrolled in 11 institutes in Taiwan
from 2009 to 2015.
Data collection
Data is collected via the case report form (CRF). Data
captured in the registry include patients’ demographics,
medical history, comorbidities, disease characteristics,
symptoms, transfusion requirements, thrombotic events,
and treatments. The lab data captured include lactate
dehydrogenase (LDH) levels, hemoglobin levels, PNH
clone sizes, renal function, and others. PNH-related
symptoms, including abdominal pain, dyspnea, short of
breath, erectile dysfunction, fatigue and hemoglobinuria
were collected via history taking by the physicians.
Baseline is defined as the start date of eculizumab for
treated patients or registry enrollment date for other
patients. Analyses are performed with available data for
each parameter. The number of patients contributing
data for each assessment might not be consistent. For
parameters that are collected only after enrollment, the
available population will reflect the patients who started
treatment after enrollment. Continuous variables were
described using standard summary statistics; categorical
variables were described using frequencies and percent-
ages. P < 0.05 was considered statistically significant.
Results
Patients’ demographics and clinical characteristics
As of 2 Dec 2015, 63 patients from 11 centers in Taiwan
were enrolled in the international PNH registry. 100 %
of patients were from Asia. Patients’ demographics and
clinical characteristics of the 63 enrolled patients are
provided in Table 1.
The median patient age at enrollment was 46 years
(rang 9–84 years), and 49.2 % of patients were female.
Median disease duration from disease onset was 4.5 years
(range from 0.1 to 34.8 years).
Similar to the ROW, most of the PNH patients in
Taiwan have PNH clone size more than 50 % (63.6 %),
whereas more than ¼ of the PNH patients have clone
size smaller than 10 % (27.3 % in Taiwan). The median
LDH level at enrollment was 4.9 fold of the upper limit
normal (ULN), higher than the ROW (P = 0.005). 80 %
of the patients had LDH higher than 1.5 fold of ULN in
Taiwan, whereas in the ROW around 58.6 % of the pa-
tients reached 1.5 fold of ULN (p = 0.039). Hemoglobin
levels in Taiwan PNH patients were also significantly
lower than the ROW (80 g/L vs. 99.0 g/L, p < 0.001).
Other parameters such as platelets 112 ×109/L, serum
creatinine 66.3 umol/L, proteinuria (12.5 % trace, 37.5 %
1+ to 4+, in 36 patients) and eGFR 95.8 mL/min were
not significantly different compared to the ROW.
6.7 % (4 out of 60) of the patients in Taiwan had a his-
tory of thrombotic events (TE), compared to 13.5 % in the
ROW (p = 0.178). 12.1 % (7 out of 58) had a history of im-
paired renal function in Taiwan, similar to 12.6 % observed
in the ROW. Symptoms such as shortness of breath
(59.3 %), erectile dysfunction (60.7 %) and hemoglobinuria
(68.5 %) in Taiwan were more common than the ROW
(41.9 %, 23.0 %, and 45.7 % respectively). The symptoms
such as fatigue (81.5 %), abdominal pain (31.5 %), and dys-
phagia (13.0 %) were not different compared to ROW.
Concomitant medication
Although the hemoglobin levels were lower in Taiwan
than the ROW, the history of RBC transfusion in Taiwan
PNH patients was 67.8 %, comparable to the ROW
(67.8 % vs 57.0 %, p = 0.274). The corticosteroid use in
Taiwan was significantly more frequent than the ROW
(53.2 % vs. 32 %, p < 0.001); whereas heparin/warfarin
and cyclosporine/ATG use in Taiwan was much lower
than the ROW, 3.3 % vs. 19.5 %, 12.9 % vs. 34.2 % re-
spectively (p < 0.001) (Table 2).
Discussion
This is the first time to have a systematic review on the
Taiwanese PNH patients. This analysis provides key
information of our PNH patients and would definitely
help understanding the basic characteristics of this rare
disease in Taiwan.
Our analysis of these 63 Taiwan PNH patients in the
international PNH registry demonstrates the median
LDH level at enrollment was 4.9 fold of the ULN,
higher than the ROW 2.0 fold. Lee et al. reported in the
similar registry data of 301 Korean PNH patients whose
LDH levels were 4.1 fold of the ULN, similar to our
finding [5].
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In our cohort, the hemoglobin level is 80 g/L, signifi-
cantly lower than 99 g/L of the ROW. In a large study
by Nishimura et al., the 209 Japanese PNH patients also
had lower hemoglobin concentration (82 g/L) compared
to the Duke patients (97 g/L) [7]. Whether these differ-
ences in hemoglobin levels reflect the basic difference
between the eastern and western populations needs fur-
ther investigation in a larger cohort.
In our analysis, some initial symptoms were quite differ-
ent between ours and the ROW patients. Significantly more
PNH patients in Taiwan had classical symptoms of PNH,
such as short of breath, hemoglobinuria, erectile dysfunc-
tion, while PNH patients in the ROW had higher incidence
of thrombosis. The reasons for this discrepancy await for
further confirmation in a larger cohort, however the short
of breath, hemoglobinuria, and erectile dysfunction could
Table 1 Patients’ demographics and clinical characteristics at enrollment into the International PNH Registry, Taiwan versus the rest
of the world (ROW)
Parameter Taiwan Patients (n = 63) ROW (n = 3857) p-value
Age, years, median (range) 46.0 (9, 84) 43.0 (0, 104) 0.331
Females, n (%) 31 (49.2) 2072 (53.7) 0.525
Age at disease start, years, median (range) 37.5 (8, 84) (n = 62) 34.0 (0, 90) (n = 3773) 0.483
Disease duration, years, median (range) 4.5 (0.1, 34.8) (n = 62) 3.0 (0.0, 100.4) (n = 3773) 0.890
GPI-Deficient Granulocytes, n (%) (n = 11) (n = 1619) 0.980
< 10 % 3 (27.3) 482 (29.8)
> =10 % to < 50 % 1 (9.1) 317 (19.6)
> = 50 % 7 (63.6) 820 (50.6)
LDH Ratio (xULN), median (Q1, Q3) 4.9 (1.9, 9.1) (n = 25) 2.0 (1.0, 5.2) (n = 2398) 0.005*
> = 1.5, n (%) 20 (80.0) 1406 (58.6) 0.039*
Hemoglobin (g/L), median (Q1, Q3) 80.0 (68.0, 105.0) (n = 51) 99.0 (84.0, 118.0) (n = 2996) <0.001*
Platelets (x109/L), median (Q1, Q3) 112.0 (51.0, 186.0) (n = 51) 114.0 (51.0, 176.0) (n = 2990) 0.680
Serum Creatinine (umol/L), median (Q1, Q3) 66.3 (53.0, 97.2) (n = 36) 73.0 (61.9, 91.0) (n = 2746) 0.36
Proteinuria, n (%) 0.056
Trace 2 (12.5) 93 (10.0)
1+ to 4+ 6 (37.5) 158 (16.9)
eGFR (mL/min), median (Q1, Q3) 95.8 (70.1, 116.5) (n = 36) 95.6 (73.9, 114.1) (n = 2638) 0.994
< 30, n (%) 3 (8.3) 62 (2.4) 0.143
30– < 60 3 (8.3) 329 (12.5)
60– < 90 8 (22.2) 726 (27.5)
> =90 22 (61.1) 1521 (57.7)
Neutrophils (x 109/L), median (Q1, Q3) 2.0 (1.0, 2.9) (n = 27) 1.9 (1.1, 2.9) (n = 2674) 0.696
History of Abdominal Pain, n (%) 17 (31.5) (n = 54) 943 (33.5) (n = 2817) 0.884
History of Dysphagia, n (%) 7 (13.0) (n = 54) 434 (15.4) (n = 2812) 0.848
History of Shortness of Breath, n (%) 32 (59.3) (n = 54) 1180 (41.9) (n = 2819) 0.012*
History of Erectile Dysfunction, n (%) 17 (60.7) (n = 28) 271 (23.0) (n = 1180) <0.001*
History of Fatigue, n (%) 44 (81.5) (n = 54) 2214 (78.5) (n = 2820) 0.738
History of Hemoglobinuria, n (%) 37 (68.5) (n = 54) 1288 (45.7) (n = 2816) 0.001*
History of Bone Marrow Disorder, n (%) 36 (58.1) (n = 62) 2265 (60.2) (n = 3762) 0.794
History of TE, n (%) 4 (6.7) (n = 60) 502 (13.5) (n = 3710) 0.178
History of any RBC Transfusion, n (%) 40 (67.8) (n = 59) 1816 (57.0) (n = 3185) 0.274
History of Impaired Renal Function, n (%) 7 (12.1) (n = 58) 456 (12.6) (n = 3609) >0.999
History of Pulmonary Hypertension, n (%) 0 (0.0) (n = 58) 68 (1.9) (n = 3670) 0.627
Ever Treated with Eculizumab, n (%) 25 (39.7) 1666 (43.2) 0.610
*p <0.05
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possibly be directly correlated with lower hemoglobin and
higher LDH levels in Taiwan.
In a recent study, Lee et al. reported the incidence of
thrombosis in the Korean National PNH Registry and
demonstrated an incidence of thrombosis of 17.9 % [5].
A retrospective French study of 460 PNH patients also
demonstrated 10-year cumulative incidence of 31 % [2].
Our investigation showed a much lower incidence of
thrombosis than the previous studies. Recently it has
been reported that the incidence of thrombosis in PNH
is likely to be underestimated as a result of subclinical
pulmonary embolism or myocardial ischemia observed
in 6 of 10 patients in one study [8] and evidence of sub-
clinical myocardial damage in 2 of 10 patients in another
study [9]. The lower incidence of thrombosis in Taiwan
PNH group is consistent with the previous observations.
In addition, the lower heparin /warfarin use may reflect
less TE observed in Taiwan PNH patients.
The corticosteroid is wildly used in Taiwan PNH pa-
tients compared to the patients in the ROW (53.2 % vs
32 %, P-value < 0.001). Corticosteroid as a treatment
option for both chronic hemolysis and acute hemolytic
exacerbations in PNH, is a subject of debate [10–12].
The main value of corticosteroid may be in attenuating
acute hemolytic exacerbations. The value of steroid in
treating chronic hemolysis is limited by toxicity. Brief
pulses of prednisone may reduce the severity and dur-
ation of the crisis while avoiding the untoward conse-
quences associated with long term use. However, in the
recent study, Jang et al. showed the corticosteroid was
the most frequently used medication in their patients
(77 %) but there was no difference in mortality between
the 104 patients who received corticosteroids for
>5.4 years (13 %) and the 197 patients who received
corticosteroid for < 5.4 years or had not received cortico-
steroid at all (15 %; P = 0.520) [13]. We should be very
cautious about the use of corticosteroid in PNH patients
due to the lack of definitive efficacy and the side effects.
Conclusions
In summary, this is the first systematic review for
Taiwan PNH patients. We will need more patients and
longer follow-up for better understanding about the
characteristics and long-term outcome of PNH patients
in Taiwan.
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